Patients eligible for coverage include those with a confirmed diagnosis of DMD and the ability to walk without wheelchair assistance. The treatment must also be medically necessary and not used experimentally, according to Humana’s policy.
Cambridge, Mass.-based Sarepta gained U.S. Food and Drug Administration approval for the drug eteplirsen in September after a months-long review process that sparked a heated internal debate.
Per patient per year, the drug costs about $300,000. Minnetonka, Minn.-based insurer UnitedHealthcare said it will cover the drug, but Indianapolis-based Anthem said it will not cover eteplirsen.
More articles about payer issues:
Federal exchange premium increases surpass Covered California hikes
Republicans call for updated tally of government subsidy expenditure
Cigna launches nationwide mobile clinic tour
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
